個股熱度排行 | 12月9日港股盤前
根據uSMART輿情監測數據,從8日晚間到9日港股盤前時間段,市場關注指數最高的3只股票是九毛九、融創中國、和鉑醫藥-B。
12月9日—港股關注排行TOP3

九毛九

關注度第一爲九毛九,該股上個交易日收盤上漲6.44%,報於20.50港元。近5個交易日累計上漲6.99%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:
九毛九:公司董事會主席管毅宏減持4800萬股 總代價8.88億港元
九毛九控股股東管毅宏減持4800萬股 套現近9億元
融創中國

關注度第二爲融創中國,該股上個交易日收盤下跌5.18%,報於4.58港元。近5個交易日累計下跌8.40%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:
融創中國發布2021年業績 核心淨虧損約253億元 獨立核數師不對綜合財務報表作出任何意見
融創2021年全年核心淨虧損約253億人幣 不派息
和鉑醫藥-B

關注度第三爲和鉑醫藥-B,該股上個交易日收盤上漲12.57%,報於1.88港元。近5個交易日累計上漲19.75%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
和鉑醫藥-B:HBM4003 0.3mg/kg加特瑞普利單抗240mg Q3W於晚期黑色素瘤患者中顯示出良好的抗腫瘤活性
和鉑醫藥-B:HBM4003聯用特瑞普利單抗治療晚期黑色素瘤顯示出良好的抗腫瘤活性
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.